Radiotherapy Combined With Endostatin and Capecitabine for NPC
Status:
Recruiting
Trial end date:
2028-08-01
Target enrollment:
Participant gender:
Summary
Radiotherapy combined with recombinant human endostatin and capecitabine for patients with
nasopharyngeal carcinoma (NPC) resistant to induction chemotherapy.